SynthesisFrontiers in neurology2023
Identifying risk factors for in-stent restenosis in symptomatic intracranial atherosclerotic stenosis: a systematic review and meta-analysis.
Synthesis in Frontiers in neurology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 10 citations in OpenAlex.
- Predictive Value of Baseline High-Resolution MRI Features for In-Stent Restenosis in Symptomatic Nonacute Intracranial Atherosclerotic Occlusion.Cardiovascular and interventional radiology · 2026Article
- Dramatically changing intracranial arteriopathy due to antiphospholipid syndrome: A case report.Radiology case reports · 2026Article
- Pre-procedural C-reactive protein levels and carotid or intracranial artery restenosis: A systematic review and meta-analysis.Atherosclerosis plus · 2026Article
- Association between Triglyceride-glucose index and coronary artery in-stent restenosis: A case-control study in an Iranian patient population.ARYA atherosclerosis · 2026Article
- Higher Time to Peak after Stent Implantation in Symptomatic High-Grade Intracranial Atherosclerotic Stenosis is Related to In-Stent Restenosis.Translational stroke research · 2025Article
- Predictive Scoring Model for In-Stent Restenosis Risk in Coronary Artery Disease Patients.Medical science monitor : international medical journal of experimental and clinical research · 2025Article
- Elucidating the benefit of drug-eluting stent for symptomatic intracranial atherosclerotic stenosis: Meta-analysis of randomized controlled trials.Surgical neurology international · 2025Review
- Safety and Efficacy of LVIS Jr Stent-assisted Coiling of Intracranial Aneurysms in Small-diameter Parent Arteries : A Single-center Experience.Clinical neuroradiology · 2024Article
- Use of the Neuroform Atlas Stent or LVIS Jr Stent for Treatment of Unruptured Intracranial Aneurysms in Parent Arteries of <2 mm in Diameter: A Multicenter Experience.AJNR. American journal of neuroradiology · 2024Article
- Delayed Displacement of Enterprise Stent in Treating Symptomatic Intracranial Atherosclerotic Stenosis: A Case Report.International medical case reports journal · 2024Article
- Evaluation of paclitaxel-coated balloon angioplasty for the treatment of symptomatic intracranial in-stent restenosis.Frontiers in neurology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: In-stent restenosis (ISR) is an adverse and notable event in the treatment of intracranial atherosclerotic stenosis (ICAS) with percutaneous transluminal angioplasty and stenting (PTAS). The incidence and contributing factors have not been fully defined. This study was performed to evaluate factors associated with ISR after PTAS. Data source: We identified studies on ISR after PTAS from an electronic search of articles in PubMed, Ovid MEDLINE, and the Cochrane Central Database (dated up to July 2022). Results: A total of 19 studies, including 452 cases of ISR after 2,047 PTAS, were included in the meta-analysis. The pooled incidence rate of in-stent restenosis was 22.08%. ISR was more likely to occur in patients with coronary artery disease (OR = 1.686; 95% CI: 1.242-2.288; Conclusions: The present study provides the current estimates of the robust effects of some risk factors for in-stent restenosis in intracranial atherosclerotic stenosis. The Enterprise stent had advantages compared with the Wingspan stent for ISR. The significant risk factors for ISR were coronary artery disease, dissection, and high residual stenosis. Local anesthesia was a suspected factor associated with ISR.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.